About F-box/LRR-repeat protein 16
F-box/LRR-repeat protein 16 (FBXL16) is a protein
from Homo sapiens identified by UniProt accession
Q8N461, 479 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | F-box/LRR-repeat protein 16 |
| UniProt accession | Q8N461 |
| Gene | FBXL16 |
| Organism | Homo sapiens |
| Length | 479 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.29
- clear cell renal carcinoma · score 0.19
- smoking behavior · score 0.11
- appendicular lean mass · score 0.10
- smoking status measurement · score 0.09
- self reported educational attainment · score 0.08
- mathematical ability · score 0.08
- smoking behaviour measurement · score 0.07
- platelet count · score 0.05
- smoking initiation · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N461-F1 | alphafold | PREDICTED | 83.18 | — |
Amino-acid sequence (479 residues)
MSSPGIDGDP KPPCLPRNGL VKLPGQPNGL GAASITKGTP ATKNRPCQPP PPPTLPPPSL AAPLSRAALA GGPCTPAGGP ASALAPGHPA ERPPLATDEK ILNGLFWYFS ACEKCVLAQV CKAWRRVLYQ PKFWAGLTPV LHAKELYNVL PGGEKEFVNL QGFAARGFEG FCLVGVSDLD ICEFIDNYAL SKKGVKAMSL KRSTITDAGL EVMLEQMQGV VRLELSGCND FTEAGLWSSL SARITSLSVS DCINVADDAI AAISQLLPNL AELSLQAYHV TDTALAYFTA RQGHSTHTLR LLSCWEITNH GVVNVVHSLP NLTALSLSGC SKVTDDGVEL VAENLRKLRS LDLSWCPRIT DMALEYVACD LHRLEELVLD RCVRITDTGL SYLSTMSSLR SLYLRWCCQV QDFGLKHLLA LGSLRLLSLA GCPLLTTTGL SGLVQLQELE ELELTNCPGA TPELFKYFSQ HLPRCLVIE
Explore F-box/LRR-repeat protein 16 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets